References

[1] D. U. Silverthorn, Human Physiology; an Integrated Approach, 8th ed. Austin, Texas: Pearson Education, Inc., 2019.

[2] S. Ralston, “Medical management of hypercalcaemia.,” Br. J. Clin. Pharmacol., vol. 34, no. 1, pp. 11–20, 1992, doi: 10.1111/j.1365-2125.1992.tb04101.x.

[3] J. Zagzag, M. I. Hu, S. B. Fisher, and N. D. Perrier, “Hypercalcemia and cancer: Differential diagnosis and treatment,” CA. Cancer J. Clin., vol. 68, no. 5, pp. 377–386, Sep. 2018, doi: 10.3322/caac.21489.

[4] “Treatment of hypercalcemia - UpToDate.” https://www.uptodate.com/contents/treatment-of-hypercalcemia (accessed Mar. 30, 2021).

[5] M. T. Drake, B. L. Clarke, and S. Khosla, “Bisphosphonates: Mechanism of action and role in clinical practice,” Mayo Clinic Proceedings, vol. 83, no. 9. Elsevier Ltd, pp. 1032–1045, 2008, doi: 10.4065/83.9.1032.

[6] A. A. Khan, P. K. Gurnani, G. D. Peksa, W. L. Whittier, and J. M. DeMott, “Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy,” Ann. Pharmacother., vol. 55, no. 3, pp. 277–285, Mar. 2021, doi: 10.1177/1060028020957048.

[7] “Treatment of hypercalcemia - UpToDate.” https://www.uptodate.com/contents/treatment-of-hypercalcemia (accessed May 06, 2021).